87292-49-7

Basic information

• Product Name: 2H-1-Benzopyran-3-ol, 2-[3,4-bis(phenylmethoxy)phenyl]-3,4-dihydro-5,7-bis(phenylmethoxy)-, (2R,3R)-
• CAS NO: 87292-49-7
• Molecular Formula: C43H38O6
• Molecular Weight: 650.771
• Mol File: 87292-49-7.mol
• Article Data: 24

Chemical Properties

• CAS DataBase Reference: 2H-1-Benzopyran-3-ol, 2-[3,4-bis(phenylmethoxy)phenyl]-3,4-dihydro-5,7-bis(phenylmethoxy)-, (2R,3R)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2H-1-Benzopyran-3-ol, 2-[3,4-bis(phenylmethoxy)phenyl]-3,4-dihydro-5,7-bis(phenylmethoxy)-, (2R,3R)-(87292-49-7)
• EPA Substance Registry System: 2H-1-Benzopyran-3-ol, 2-[3,4-bis(phenylmethoxy)phenyl]-3,4-dihydro-5,7-bis(phenylmethoxy)-, (2R,3R)-(87292-49-7)

Safety Data

• Hazardous Substances Data: 87292-49-7(Hazardous Substances Data)

Upstream product

• 100-39-0 benzyl bromide 
• 490-46-0 (2R,3R)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-1[2H]-benzopyran-3,5,7-triol 
• 100-44-7 benzyl chloride 
• 5447-02-9 3,4-dibenzyloxybenzaldehyde 
• 63604-98-8 1,3-dibenzylphloroglucinol 
• 20728-73-8 5,7,3',4'-tetra-O-benzyl-(+)-catechin 
• 203571-40-8 3-(3,4-bis-benzyloxy-phenyl)-acrylic acid ethyl ester 
• 362632-29-9 (E)-3-(3,4-bis(benzyloxy)phenyl)prop-2-en-1-ol 
• 732298-08-7 (E)-3-[2,4-bis(benzyloxy)-6-hydroxyphenyl]-1-[3,4-bis(benzyloxy)phenyl]propene 
• 732298-11-2 (+)-(1S,2S)-3-[2,4-bis(benzyloxy)-6-hydroxyphenyl]-1-[3,4-bis(benzyloxy)phenyl]propane-1,2-diol 
• 918157-97-8 (E)-3-[2,4-bis(benzyloxy)-6-(tert-butyldimethylsilyloxy)phenyl]-1-[3,4-bis(benzyloxy)phenyl]propene 
• 918158-03-9 (1S,2S)-3-[2,4-Bis-benzyloxy-6-(tert-butyl-dimethyl-silanyloxy)-phenyl]-1-(3,4-bis-benzyloxy-phenyl)-propane-1,2-diol 
• 154-23-4 catechin 
• 16198-01-9 (-)-epicatechin pentaacetate 

Downstream Products

• 666233-43-8 (2R,3R)-5,7,3',4'-tetrabenzyloxyflavan-3-yl glutarate 
• 223387-26-6 3’,4’,5,7-tetra-O-benzyl-4β-(2-hydroxyethyloxy)epicatechin 
• 664351-48-8 [4,8']-2,3-trans-3,4-trans:2',3'-cis-octa-O-benzyl-3-O-acetyl-(+)-catechin-(-)-epicatechin 
• 71634-82-7 (2R,3R)-3',4',5,7-tetrahydroxyflavan-3-yl hexadecanoate 
• 490-46-0 (2R,3R)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-1[2H]-benzopyran-3,5,7-triol 
• 1126481-88-6 C₈₅⁽¹⁴⁾CH₇₄O₁₂ 
• 1282609-52-2 C₂₅H₂₄O₁₁ 
• 1312298-11-5 C₅₁H₄₄O₇ 
• 1312298-12-6 C₅₅H₅₀O₈ 
• 1312298-14-8 C₆₀H₅₂O₈ 
• 1312298-16-0 C₂₀H₂₂O₈ 
• 1312298-17-1 C₁₈H₁₈O₈ 
• 1312298-21-7 C₁₈H₁₆O₇ 
• 88191-48-4 (-)-epicatechin 

Relevant articles and documents

Synthesis of novel (?)-epicatechin derivatives as potential endothelial GPER agonists: Evaluation of biological effects

To potentially identify proteins that interact (i.e. bind) and may contribute to mediate (?)-epicatechin (Epi) responses in endothelial cells we implemented the following strategy: 1) synthesis of novel Epi derivatives amenable to affinity column use, 2)

NOVEL ANALOGUES OF EPICATECHIN AND RELATED POLYPHENOLS

The present invention provides novel analogues of epicatechin and related polyphenols, their variously functionalized derivatives, process for preparation of the same, composition comprising these compounds and their method of use.

Design, synthesis and characterization of novel inhibitors against mycobacterial β-ketoacyl CoA reductase FabG4

We report the design and synthesis of triazole-polyphenol hybrid compounds 1 and 2 as inhibitors of the FabG4 (Rv0242c) enzyme of Mycobacterium tuberculosis for the first time. A major advance in this field occurred only a couple of years ago with the X-ray crystal structure of FabG4, which has helped us to design these inhibitors by the computational fragment-based drug design (FBDD) approach. Compound 1 has shown competitive inhibition with an inhibition constant (Ki) value of 3.97 ± 0.02 μM. On the other hand, compound 2 has been found to be a mixed type inhibitor with a Ki value of 0.88 ± 0.01 μM. Thermodynamic analysis using isothermal titration calorimetry (ITC) reveals that both inhibitors bind at the NADH co-factor binding domain. Their MIC values, as determined by resazurin assay against M. smegmatis, indicated their good anti-mycobacterial properties. A preliminary structure-activity relationship (SAR) study supports the design of these inhibitors. These compounds may be possible candidates as lead compounds for alternate anti-tubercular drugs. All of the reductase enzymes of the Mycobacterium family have a similar ketoacyl reductase (KAR) domain. Hence, this work may be extrapolated to find structure-based inhibitors of other reductase enzymes. The Royal Society of Chemistry.